vs

Side-by-side financial comparison of KENNAMETAL INC (KMT) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

KENNAMETAL INC is the larger business by last-quarter revenue ($529.5M vs $321.1M, roughly 1.6× MADRIGAL PHARMACEUTICALS, INC.). KENNAMETAL INC runs the higher net margin — 6.4% vs -18.2%, a 24.6% gap on every dollar of revenue. On growth, MADRIGAL PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (210.8% vs 9.8%). KENNAMETAL INC produced more free cash flow last quarter ($42.4M vs $-133.8M).

Kennametal, Inc. is a manufacturer of high-performance cutting tools and engineered components used in the aerospace, defense, transportation and oil and gas drilling industries. Its customer base is global.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

KMT vs MDGL — Head-to-Head

Bigger by revenue
KMT
KMT
1.6× larger
KMT
$529.5M
$321.1M
MDGL
Growing faster (revenue YoY)
MDGL
MDGL
+200.9% gap
MDGL
210.8%
9.8%
KMT
Higher net margin
KMT
KMT
24.6% more per $
KMT
6.4%
-18.2%
MDGL
More free cash flow
KMT
KMT
$176.3M more FCF
KMT
$42.4M
$-133.8M
MDGL

Income Statement — Q2 FY2026 vs Q4 FY2025

Metric
KMT
KMT
MDGL
MDGL
Revenue
$529.5M
$321.1M
Net Profit
$33.9M
$-58.6M
Gross Margin
32.8%
Operating Margin
9.9%
-18.6%
Net Margin
6.4%
-18.2%
Revenue YoY
9.8%
210.8%
Net Profit YoY
89.0%
1.4%
EPS (diluted)
$0.44
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
KMT
KMT
MDGL
MDGL
Q4 25
$529.5M
$321.1M
Q3 25
$498.0M
$287.3M
Q2 25
$516.4M
$212.8M
Q1 25
$486.4M
$137.3M
Q4 24
$482.1M
$103.3M
Q3 24
$481.9M
$62.2M
Q2 24
$543.3M
Q1 24
$515.8M
$0
Net Profit
KMT
KMT
MDGL
MDGL
Q4 25
$33.9M
$-58.6M
Q3 25
$23.3M
$-114.2M
Q2 25
$21.6M
$-42.3M
Q1 25
$31.5M
$-73.2M
Q4 24
$17.9M
$-59.4M
Q3 24
$22.1M
$-107.0M
Q2 24
$37.2M
Q1 24
$19.0M
$-147.5M
Gross Margin
KMT
KMT
MDGL
MDGL
Q4 25
32.8%
Q3 25
31.0%
Q2 25
28.2%
Q1 25
32.1%
96.7%
Q4 24
30.1%
Q3 24
31.3%
Q2 24
31.5%
Q1 24
29.7%
Operating Margin
KMT
KMT
MDGL
MDGL
Q4 25
9.9%
-18.6%
Q3 25
7.5%
-39.7%
Q2 25
6.1%
-22.2%
Q1 25
9.1%
-57.8%
Q4 24
6.6%
-64.8%
Q3 24
7.5%
-187.1%
Q2 24
11.3%
Q1 24
6.8%
Net Margin
KMT
KMT
MDGL
MDGL
Q4 25
6.4%
-18.2%
Q3 25
4.7%
-39.8%
Q2 25
4.2%
-19.9%
Q1 25
6.5%
-53.4%
Q4 24
3.7%
-57.5%
Q3 24
4.6%
-172.0%
Q2 24
6.8%
Q1 24
3.7%
EPS (diluted)
KMT
KMT
MDGL
MDGL
Q4 25
$0.44
$-2.55
Q3 25
$0.30
$-5.08
Q2 25
$0.28
$-1.90
Q1 25
$0.41
$-3.32
Q4 24
$0.23
$-2.50
Q3 24
$0.28
$-4.92
Q2 24
$0.47
Q1 24
$0.24
$-7.38

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
KMT
KMT
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$129.3M
$198.7M
Total DebtLower is stronger
$597.2M
$339.9M
Stockholders' EquityBook value
$1.3B
$602.7M
Total Assets
$2.6B
$1.3B
Debt / EquityLower = less leverage
0.45×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
KMT
KMT
MDGL
MDGL
Q4 25
$129.3M
$198.7M
Q3 25
$103.5M
$295.7M
Q2 25
$140.5M
$186.2M
Q1 25
$97.5M
$183.6M
Q4 24
$121.2M
$100.0M
Q3 24
$119.6M
$232.7M
Q2 24
$128.0M
Q1 24
$92.1M
$622.5M
Total Debt
KMT
KMT
MDGL
MDGL
Q4 25
$597.2M
$339.9M
Q3 25
$597.0M
$339.8M
Q2 25
$596.8M
$118.4M
Q1 25
$596.6M
$118.0M
Q4 24
$596.4M
$117.6M
Q3 24
$596.2M
$117.1M
Q2 24
$596.0M
Q1 24
$595.8M
$116.1M
Stockholders' Equity
KMT
KMT
MDGL
MDGL
Q4 25
$1.3B
$602.7M
Q3 25
$1.3B
$625.7M
Q2 25
$1.3B
$696.0M
Q1 25
$1.2B
$710.6M
Q4 24
$1.2B
$754.4M
Q3 24
$1.3B
$777.2M
Q2 24
$1.2B
Q1 24
$1.3B
$850.8M
Total Assets
KMT
KMT
MDGL
MDGL
Q4 25
$2.6B
$1.3B
Q3 25
$2.5B
$1.4B
Q2 25
$2.5B
$1.0B
Q1 25
$2.5B
$996.6M
Q4 24
$2.4B
$1.0B
Q3 24
$2.5B
$1.1B
Q2 24
$2.5B
Q1 24
$2.5B
$1.1B
Debt / Equity
KMT
KMT
MDGL
MDGL
Q4 25
0.45×
0.56×
Q3 25
0.46×
0.54×
Q2 25
0.46×
0.17×
Q1 25
0.48×
0.17×
Q4 24
0.49×
0.16×
Q3 24
0.47×
0.15×
Q2 24
0.48×
Q1 24
0.47×
0.14×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
KMT
KMT
MDGL
MDGL
Operating Cash FlowLast quarter
$55.1M
$-133.5M
Free Cash FlowOCF − Capex
$42.4M
$-133.8M
FCF MarginFCF / Revenue
8.0%
-41.7%
Capex IntensityCapex / Revenue
2.4%
0.1%
Cash ConversionOCF / Net Profit
1.63×
TTM Free Cash FlowTrailing 4 quarters
$99.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
KMT
KMT
MDGL
MDGL
Q4 25
$55.1M
$-133.5M
Q3 25
$17.5M
$79.8M
Q2 25
$78.6M
$-47.1M
Q1 25
$28.8M
$-88.9M
Q4 24
$55.2M
$-104.5M
Q3 24
$45.7M
$-67.0M
Q2 24
$113.6M
Q1 24
$75.2M
$-149.2M
Free Cash Flow
KMT
KMT
MDGL
MDGL
Q4 25
$42.4M
$-133.8M
Q3 25
$-5.5M
$79.0M
Q2 25
$57.1M
Q1 25
$5.3M
Q4 24
$35.9M
$-104.7M
Q3 24
$21.0M
$-67.8M
Q2 24
$90.3M
Q1 24
$48.4M
$-149.5M
FCF Margin
KMT
KMT
MDGL
MDGL
Q4 25
8.0%
-41.7%
Q3 25
-1.1%
27.5%
Q2 25
11.1%
Q1 25
1.1%
Q4 24
7.5%
-101.3%
Q3 24
4.4%
-109.0%
Q2 24
16.6%
Q1 24
9.4%
Capex Intensity
KMT
KMT
MDGL
MDGL
Q4 25
2.4%
0.1%
Q3 25
4.6%
0.3%
Q2 25
4.2%
0.0%
Q1 25
4.8%
0.0%
Q4 24
4.0%
0.2%
Q3 24
5.1%
1.3%
Q2 24
4.3%
Q1 24
5.2%
Cash Conversion
KMT
KMT
MDGL
MDGL
Q4 25
1.63×
Q3 25
0.75×
Q2 25
3.64×
Q1 25
0.92×
Q4 24
3.08×
Q3 24
2.07×
Q2 24
3.06×
Q1 24
3.96×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

KMT
KMT

Metal Cutting$331.1M63%
Infrastructure$198.5M37%

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons